R&D Cost Increase May Reflect Comparative Trials; Can Biotech Keep Up?

The sharp increase in the average spending on clinical trials in the pharmaceutical industry may reflect increasing pressure to demonstrate advantages over marketed products, Tufts Center for the Study of Drug Development Director of Economic Analysis Joseph DiMasi, PhD, suggested during a Nov. 30 conference in Philadelphia